- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Further information:
- The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate your product is following confirmation from clinicians that diltiazem has been used in clinical practice for some time and a published evidence summary (ESUOM3) being available. Therefore, proceeding to a NICE evaluation is not likely to add any further value to the system. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12100
Email enquiries
If you have any queries please email [email protected]
For further information on how we select topics for development, please see our page about prioritising our guidance topics